Drug Trial Radar · NCT03560193
Randomized Trial of 2% Chlorhexidine-70% Isopropanol vs 5% Povidone Iodine-69% Ethanol for Skin Antisepsis in Reducing Surgical-site Infection After Cardiac Surgery
Last checked: Nov 19, 2026Latest source record: Jun 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,316
Actual
Start
Sep 10, 2018
Primary completion
May 25, 2022
Study completion May 25, 2022
Sponsor
- Lead sponsor
- Poitiers University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Despite completion of more than 9 million procedures each year in France, the best antiseptic solution to be used for preparing the skin to reduce risk of surgical site infection (SSI) remains unknown. 2% Chlorhexidine gluconate (CHG)-alcohol is superior to Povidone Iodine (PVI)-alcohol for short term vascular catheter care (Mimoz O, Lancet 2015; Pages J, Intensive Care Med 2016), but studies comparing both antiseptic solutions for clean-contaminated surgical procedures led to conflicting results. The present study will be the first large scale multicenter randomized controlled trial adequately powered to compare efficacy and safety of CHG-alcohol over PVI-alcohol in reducing SSI after clean surgery. A clean surgery was chosen because pathogens involved in SSI mostly originate from skin. Therefore, optimisation of skin disinfection before surgery has the potential to reduce the incidence of SSI. Cardiac surgery was chosen because SSI may be severe, diagnosis of SSI is easy to monitor and to define and infections arise earlier than other frequent clean surgeries using implants such as orthopaedic or vascular surgery. The incidence of reoperation for any purpose will be used as the main objective because there are easy to track and define and are less susceptible to interpretation in an open trial than superficial SSI. According to CDC criteria, patients will be monitored up to Day 90 because mediastinitis after cardiac surgery may occur after the usual 30-day SSI surveillance period.
Conditions
- Cardiac Surgery in Adult Patient
Interventions
2%Chlorhexidine-70%IsopropanolDrug
2% Chlorhexidine-70% isopropanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
5%Povidone Iodine- 69%EthanolDrug
5%Povidone Iodine- 69%Ethanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of any re-sternotomy occurring between Day 0 and Day 90 after surgeryTime frame: 90 days
- Incidence of any reoperation on saphen venous/radial artery site occurring between Day 0 and Day 30 after surgery.Time frame: 30 days
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
University Hospital of Clermont-Ferrand
Clermont-Ferrand, France
University Hospital of Nantes
Nantes, France
La Pitié Salpétrière Hospital
Paris, France
Institut Mutualiste Montsouris
Paris, France
University Hospital of Poitiers
Poitiers, France
University Hospital of Rennes
Rennes, France
CHRU de Strasbourg
Strasbourg, France
CHU de Toulouse
Toulouse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.